Home Blog Page 8

NPM1 Mutation Test: AML Prognosis, Leukemia Genetics, and Results

Learn how NPM1 mutation testing classifies AML, affects prognosis, and supports sensitive MRD monitoring, including positive, negative, VAF, and treatment results.

An NPM1 mutation test looks for acquired changes in the nucleophosmin 1 gene in blood or bone marrow. NPM1 mutations occur in about one-third...

NRAS Mutation Test: Melanoma, Colon Cancer, and Results

Understand NRAS mutation test results in melanoma and colorectal cancer, including extended RAS coverage, anti-EGFR resistance, treatment relevance, and test limits.

An NRAS mutation test looks for acquired tumor changes that keep the RAS–MAPK growth pathway active. It is most often included in molecular testing...

NTRK Fusion Test: Cancer Targeted Therapy, Gene Fusion, and Results

Learn how NTRK fusion testing finds tumor-agnostic targets, compares RNA NGS, DNA NGS, IHC, and FISH, and guides TRK inhibitor treatment and resistance testing.

An NTRK fusion test looks for an abnormal joining of NTRK1, NTRK2, or NTRK3 with another gene. The fusion creates a continuously active TRK...

PALB2 Genetic Test: Breast Cancer Risk, Mutations, and Results

Learn what PALB2 genetic testing shows, how pathogenic variants affect breast, pancreatic, and ovarian cancer risk, and how positive, negative, and VUS results guide care.

A PALB2 genetic test looks for an inherited variant in a gene that works with BRCA1 and BRCA2 to repair broken DNA. A pathogenic...

PDGFRA Mutation Test: GIST, Targeted Therapy, and Results

Learn how PDGFRA mutation testing guides GIST diagnosis and therapy, including D842V, exon 18 results, imatinib resistance, avapritinib, and follow-up.

A PDGFRA mutation test looks for acquired changes in platelet-derived growth factor receptor alpha, most often in a suspected or confirmed gastrointestinal stromal tumor...

PD-L1 Test: Cancer Immunotherapy, Expression Score, and Results

Learn how PD-L1 testing guides cancer immunotherapy, including TPS, CPS, assay clones, positive and negative scores, cancer-specific cutoffs, and test limitations.

A PD-L1 test uses immunohistochemistry to measure programmed death ligand 1 protein in a tumor sample. The result can help select immune checkpoint inhibitor...

PIK3CA Mutation Test: Breast Cancer, Targeted Therapy, and Results

Learn how PIK3CA mutation testing guides targeted therapy in HR-positive, HER2-negative advanced breast cancer, including tissue, plasma, alpelisib, and inavolisib results.

A PIK3CA mutation test looks for acquired changes in the gene that encodes the p110-alpha subunit of PI3K, a central growth and survival pathway....

PML-RARA Test: Acute Promyelocytic Leukemia, Fusion Gene, and Results

Learn how PML-RARA testing confirms acute promyelocytic leukemia, compares FISH with RT-PCR, guides ATRA and arsenic treatment, and monitors molecular remission.

A PML-RARA test detects the fusion gene that defines acute promyelocytic leukemia (APL), a highly treatable but immediately dangerous subtype of acute myeloid leukemia....

PMS2 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn what an PMS2 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

An PMS2 genetic test looks for an inherited change in the PMS2 gene that prevents DNA mismatch repair from working normally. A pathogenic germline...

PTEN Genetic Test: Cowden Syndrome, Cancer Risk, and Results

Learn how PTEN genetic testing can confirm Cowden syndrome, clarify cancer risks, explain positive, negative, and VUS results, and guide screening for patients and families.

A PTEN genetic test looks for an inherited pathogenic variant in the PTEN tumor-suppressor gene. A positive germline result can confirm PTEN hamartoma tumor...

RB1 Genetic Test: Retinoblastoma, Cancer Risk, and Results

Understand how RB1 genetic testing identifies heritable retinoblastoma, clarifies blood and tumor results, guides eye surveillance, and defines cancer and family risks.

An RB1 genetic test determines whether a child or adult carries a disease-causing change in the RB1 tumor-suppressor gene. The test is central to...

RET Fusion Test: Lung and Thyroid Cancer, Targeted Therapy, and Results

Learn how RET fusion testing detects targetable drivers in lung and thyroid cancer, how RNA and DNA methods differ, and what positive, negative, and resistance results mean.

A RET fusion test looks for an acquired rearrangement that joins part of the RET gene to another gene inside cancer cells. The fusion...

RET Genetic Test: MEN2, Medullary Thyroid Cancer, and Results

Learn how germline RET testing confirms MEN2, guides medullary thyroid cancer prevention, explains variant results, and directs pheochromocytoma screening and family testing.

A germline RET genetic test looks for an inherited activating variant that causes multiple endocrine neoplasia type 2, or MEN2. MEN2 creates a high...

ROS1 Fusion Test: Lung Cancer, Targeted Therapy, and Results

Learn how a ROS1 fusion test detects an actionable lung cancer driver, how tissue and blood methods differ, and what positive, negative, and resistance results mean.

A ROS1 fusion test looks for a rearrangement that joins part of the ROS1 gene to another gene and creates an abnormal growth signal...

SDHB Genetic Test: Paraganglioma, Pheochromocytoma, and Cancer Risk

Understand what an SDHB genetic test shows, how results affect paraganglioma and pheochromocytoma surveillance, metastatic risk, and testing for relatives.

An SDHB genetic test looks for an inherited pathogenic variant in a gene that helps mitochondria process energy and restrain abnormal cell growth. A...

SDHC Genetic Test: Paraganglioma, Pheochromocytoma, and Results

Learn how an SDHC genetic test identifies hereditary paraganglioma risk, what positive, negative, and VUS results mean, and how carrier surveillance works.

An SDHC genetic test looks for an inherited pathogenic variant that increases susceptibility to paraganglioma and, less often, pheochromocytoma. SDHC is part of the...

SDHD Genetic Test: Paraganglioma, Pheochromocytoma, and Results

Learn how an SDHD genetic test identifies hereditary paraganglioma risk, why paternal inheritance matters, and how positive, negative, and uncertain results guide surveillance.

An SDHD genetic test looks for an inherited pathogenic variant that predisposes to paragangliomas and pheochromocytomas. SDHD-associated disease often involves multiple head and neck...

Solid Tumor NGS Panel Test: Cancer Mutations, Fusions, and Treatment Results

Learn how a solid tumor NGS panel detects cancer mutations, fusions, copy-number changes, and biomarkers, and how results may guide treatment, trials, and repeat testing.

A solid tumor next-generation sequencing panel examines many cancer-related genes at the same time. It can detect mutations, small insertions or deletions, copy-number changes,...

STK11 Genetic Test: Peutz-Jeghers Syndrome, Cancer Risk, and Results

Learn what an STK11 genetic test shows, how Peutz-Jeghers syndrome affects polyps and cancer risk, and what positive, negative, and VUS results mean for surveillance.

An STK11 genetic test looks for an inherited pathogenic variant that causes Peutz-Jeghers syndrome. This condition is characterized by hamartomatous polyps, dark freckle-like pigmentation...

TET2 Mutation Test: Blood Cancer, Clonal Hematopoiesis, and Results

Learn what a TET2 mutation test shows, why the same result can mean CHIP, CCUS, or blood cancer, and how VAF, co-mutations, and blood counts guide follow-up.

A TET2 mutation test looks for acquired DNA changes in blood-forming cells. TET2 mutations are common in clonal hematopoiesis, a state in which one...